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Polycystic ovary syndrome (PCOS) is a reproductive and metabolic disorder correlated with several risk factors for atherosclerosis.1 Previous studies have 
shown that the prevalence of cardiovascular disease 
(CVD) in subjects with PCOS is high compared 
with the normal population.2,3 Evaluation of 
preclinical vascular disease using noninvasive tests 
in patients with PCOS with greater carotid intima-
media thickness (CIMT) has demonstrated that 
there is an increased tendency to atherosclerosis in 
these patients compared with healthy controls.4,5 
Also, some studies have indicated that increased 
CIMT as a noninvasive marker is a powerful 
predictor of coronary events and is associated with 
traditional cardiovascular risk factors, including age, 
obesity, and metabolic profiles especially increased 
inflammatory markers.6,7
Antiatherogenic effects such as improving 
endothelial function, inhibiting platelet aggregation, 
and reducing levels of triglycerides of omega-3 
were previously reported.8 A cross-sectional study 
observed that higher consumption of omega-3 was 
associated with a lower prevalence odds of carotid 
plaques and a lesser thickness of segment-specific 
CIMT.9 However, no significant effect on CIMT was 
seen following supplementation with 1 g of omega-3 
over 4.9 years in people with CVD and/or CVD risk 
factors and dysglycemia.10 Several large observational 
and arterial imaging studies have demonstrated that 
daily consumption of 100 IU of vitamin E for at least 
two years decreased atherosclerosis progression and 
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A B S T R AC T
Objectives: We sought to evaluate the effects of omega-3 and vitamin E co-
supplementation on carotid intima-media thickness (CIMT) and inflammatory factors 
in patients with polycystic ovary syndrome (PCOS). Methods: This randomized, double-
blind, placebo-controlled trial was done among 60 women with PCOS. Participants 
were randomly assigned into two groups (n = 30 each group) and assigned to take 
either 1000 mg omega-3 plus 400 IU vitamin E supplements or a placebo for 12 weeks. 
Results: Compared with placebo, omega-3 and vitamin E co-supplementation led to 
significant decreases in maximum levels of left CIMT (-0.006±0.006 vs. +0.002±0.007 mm, 
p < 0.001), mean levels of left CIMT (-0.005±0.006 vs. +0.002±0.010 mm, p = 0.010), 
maximum levels of right CIMT (-0.006±0.010 vs. +0.006±0.010 mm, p = 0.010), and 
mean levels of right CIMT (-0.005±0.005 vs. +0.001±0.010 mm, p = 0.020). Change in 
high-sensitivity C-reactive protein (hs-CRP) (-390.6±942.9 vs. +237.0±754.3 ng/mL, 
p = 0.006) was significantly different between the supplemented patients and placebo 
group. We did not observe any significant effect in plasma nitric oxide (NO) values 
following supplementation with omega-3 plus vitamin E compared with the placebo. 
Conclusions: Co-supplementation with omega-3 and vitamin E for 12 weeks among 
patients with PCOS had beneficial effects on CIMT and serum hs-CRP values, but 
unchanged NO values.
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CVD event rates.11,12 However, in another study, 
vitamin E supplementation (400 IU) in healthy men 
and women at low risk for CVD did not reduce the 
progression of CIMT over a three-year period.13
The effects of omega-3 and vitamin E 
co-supplementation on metabolic profiles have been 
investigated previously.14,15 Omega-3 and vitamin E 
co-supplementation seems to work better than single 
supplementation. The effects of omega-3 and/or 
vitamin E supplements on human atherosclerosis 
progression were evaluated in a few small studies in 
subjects without PCOS, which were inconclusive. 
The current investigation was, therefore, done 
to assess the impacts of omega-3 and vitamin E 
co-supplementation on CIMT and inflammatory 
factors in patients with PCOS.
M ET H O D S
This randomized, double-blind, placebo-controlled 
clinical trial, registered on the Iranian website for 
registration of clinical trials (http://www.irct.ir: 
IRCT201511015623N57) was conducted among 
60 subjects with PCOS diagnosed according to the 
Rotterdam criteria,16 aged 18–40 years old who 
were referred to the Naghavi Clinic in Kashan, Iran, 
between June 2016 and October 2016. We excluded 
pregnant women and those with endocrine diseases 
and no hormonal treatments in the six months 
before the study. This trial was approved by the 
ethics committee of Kashan University of Medical 
Sciences (KAUMS), and informed consent was 
taken from all subjects. Subjects were randomly 
divided into two groups (n = 30 each group) to 
receive either 1000 mg omega-3 from flaxseed oil 
containing 400 mg α-linolenic acid plus 400 IU 
vitamin E supplements or a placebo for 12 weeks. 
The supplement and placebo (paraffin) were 
provided by barij Essence Pharmaceutical Company 
(Kashan, Iran).
To evaluate compliance, we counted the 
remaining supplements. To increase compliance, all 
women received short messages every day reminding 
them to take the capsules.
We considered CIMT as primary outcome 
measurement and inflammatory parameters as 
secondary outcomes measurements.
CIMT measurements (maximum and mean of 
left and right CIMT) were done in patients at the 
2 cm distance of the common carotid bifurcation 
[Figure 1], by the same sonographer, at baseline 
and after the 12-week intervention using a Doppler 
ultrasonography device (Samsung Medison V20, 
Korea) with linear multi-frequencies of 7.5- to 
10-MHz probe. Reproducibility information 
was obtained from the duplicate ultrasound 
examinations at baseline and the end of the trial. 
The mean±standard deviation (SD) difference 
in common CIMT between the two baseline 
measurements (screening visit and randomization 
visit) was 0.0004±0.058 mm. The mean absolute 
mean difference was 0.037±0.042 mm. The intra- 
and interobserver coefficient variances (CVs) for the 
repeated measurements of mean CIMT were 6.5% 
and 9.6%, respectively. Furthermore, the intra- and 
interobserver CVs for the repeated measurements of 
maximum CIMT were 7.0% and 10.5%, respectively. 
All CIMT (mean and maximum thickness) 
measurements were evaluated blindly by a single 
experienced ultrasonographer.
Fasting blood samples (10 mm) were collected 
at baseline and after the 12-week treatment. Serum 
high-sensitivity C-reactive protein (hs-CRP) values 
were quantified by an ELISA kit (LDN, Nordhorn, 
Germany) with inter- and intra-assay CVs of lower 
than 7.0%. Plasma nitric oxide (NO) values were 
evaluated using the Griess method17 with inter- and 
intra-assay CVs < 5.0%.
To establish normal data distribution, we 
used the Kolmogorov-Smirnov test. To establish 
differences in anthropometric measures between 
the two groups, we applied the independent samples 
Tip of the ow 
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Figure 1: Placement of the ultrasonographic 
calipers to measure carotid intima-media thickness 
(CIMT).
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t-test. The intention-to-treat (ITT) analysis of 
the primary study end-point was applied to all 
randomly allocated subjects. To determine the 
effects of omega-3 and vitamin E co-supplements on 
CIMT and inflammatory markers, we used one-way 
repeated measures ANOVA. To evaluate for several 
confounders, we adjusted all analyses for baseline 
values, age, and baseline body mass index (bMI) 
to avoid potential bias using ANCOVA. A p-value 
< 0.050 was considered statistically significant. All 
data entry and statistical analyses were conducted 
using the SPSS Statistics (SPSS Inc. Released 
2009. PASW Statistics for Windows, Version 18.0. 
Chicago: SPSS Inc.).
We used a randomized clinical trial sample size 
calculation formula where type one (α) and type 
two (β) errors were 0.05, and 0.20 (power = 80%), 
respectively. According to a previous trial,18 we used 
0.18 mm as SD and 0.15 mm as the change in mean 
(effect size) of CIMT as a main variable. based on 
the sample size calculation formula, we needed 25 
subjects in each group. After considering five dropouts 
in each group, the final sample size was 30 subjects in 
each group.
R E S U LTS
Three patients in the omega-3 and vitamin E 
co-supplements group and three in the placebo 
group withdrew from the study due to personal 
reasons and, therefore, did not complete the trial 
[Figure 2]. However, all 60 subjects were included 
in the final analysis using the ITT principle.
There were no significant differences between the 
two groups in mean age, height, weight, and bMI at 
baseline, and changes in weight and bMI at the end 
of the study (data not shown).
Omega-3 and vitamin E co-supplementation 
led to significant decreases in maximum levels of 
left CIMT (-0.006±0.006 vs. +0.002±0.007 mm, 
p < 0.001), mean left CIMT levels (-0.005±0.006 
vs. +0.002±0.010 mm, p = 0.010), maximum levels 
of right CIMT (-0.006±0.010 vs. +0.006±0.010 
mm, p = 0.010), and mean right CIMT levels 
(-0.005±0.005 vs. +0.001±0.010 mm, p = 0.020) 
after the 12-week intervention compared with 
placebo [Table 1]. Change in hs-CRP (-390.6±942.9 
vs. +237.0±754.3 ng/mL, p = 0.006) was 
significantly different between the intervention and 
placebo group. We did not observe any significant 
effect on NO values between the two groups at the 
end of the study.
There was a significant difference in baseline 
levels of NO (p = 0.080) between the two groups. 
When we adjusted the analysis for baseline values of 
biochemical parameters, age and baseline bMI, mean 
right CIMT (p = 0.070) became non-significant, 
while other findings did not alter [Table 2].
Assessed for eligibility (n = 75)
Randomized (n = 60)
Placebo group (n = 30) Intervention group (n = 30)
Lost to follow-up (n = 3)
Withdrew (n = 3)
Lost to follow-up (n = 3)
Withdrew (n = 3)
Analyzed (n = 30)
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Figure 2: Patient flow diagram.
476 Ha m i d  R e z a  Ta l a r i ,  et  a l .
O M A N  M E D  J,  V O L  3 3 ,  N O  6 ,  N O V E M b E R  2 0 1 8
477Ha m i d  R e z a  Ta l a r i ,  et  a l .
D I S C U S S I O N
To the best of our knowledge, this study is the first 
of its kind. We evaluated the beneficial effects of 
omega-3 and vitamin E co-supplementation on 
CIMT and inflammatory parameters among patients 
with PCOS. We found that co-supplementation 
with omega-3 and vitamin E for 12 weeks in patients 
with PCOS had beneficial effects on CIMT and 
hs-CRP levels, but did not affect NO values.
Omega-3 and vitamin E co-supplementation 
resulted in a significant reduction in maximum 
and mean levels of left and right CIMT in patients 
with PCOS compared with placebo. Another study 
observed an inverse relationship between fetal 
growth and arterial wall thickness in childhood, 
which can be prevented by dietary omega-3 
supplementation in the first five years of life.19 In 
addition, supplementation with 3 g/day omega-3 
for six months in patients undergoing hemodialysis 
decreased CIMT.18 The favorable effectiveness 
of omega-3 on CIMT progression in people with 
combined hyperlipoproteinemia was also reported.20 
Co-supplementation with vitamins E (136 IU/day) 
and C (250 mg/day) in hypercholesterolemic men 
for six years reduced common carotid artery (CCA)-
IMT.21 Our findings are inconsistent with the 
results of previous studies examining the effects on 
carotid and coronary atherosclerosis,22–24 as well as a 
recent meta-analysis of the effects of omega-3 fatty 
acids on clinical outcomes.25 In addition, vitamin 
E supplementation (1200 IU/day) for two years 
in patients with coronary artery disease reduced 
parameters of inflammation and oxidative stress, 
but had no significant effect on CIMT.26 It must 
be kept in mind that beneficial effects of omega-3 
fatty acids or vitamin E on CIMT in most previous 
studies were observed after six months, while in our 
study, the beneficial effects of omega-3 and vitamin 
E co-supplementation on CIMT were seen after 
three months. This may due to co-supplementation 
working better than single supplementation. 
However, data on CVD events in women with PCOS 
are limited, but a recent meta-analysis demonstrated 
that women with PCOS had twice the relative 
risk of CVD or stroke than control patients.27 In a 
meta-analysis study, CIMT artery in women with 
PCOS was significantly higher than healthy women. 
CIMT has been widely used as a surrogate index 
of atherosclerosis and CVD events.28,29 Omega-3 
may mitigate the adverse effects of reduced Δ-5 Ta
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desaturase activity,19 which in turn may improve 
CIMT. Moreover, omega-3 supplementation 
appears to have a cardioprotective effect in adults, 
potentially through effects on lipid fractions, 
endothelial function, and/or antiarrhythmic and 
anti-inflammatory actions.30 Vitamin E intake due 
to its antioxidant and anti-inflammatory effects may 
improve CIMT. 21
Omega-3 and vitamin E co-supplementation in 
patients with PCOS for 12 weeks was associated 
with a significant reduction in hs-CRP levels, but 
unchanged NO values. Supporting our results, Rizza 
et al,31 observed that supplementation with omega-3 
(2 g/day) significantly improved endothelial function 
and decreased pro-inflammatory markers in offspring 
of patients with type 2 diabetes mellitus for 12 weeks. 
In addition, another meta-analysis study observed 
that marine-derived omega-3 supplementation had a 
significant CRP lowering effect.32 We have previously 
shown beneficial effects of six-weeks omega-3 
supplementation (1000 mg/day) on hs-CRP levels 
among women with gestational diabetes mellitus 
(GDM).33 Likewise, three weeks of supplementation 
with 200 mg/day vitamin E caused a significant 
decrease in CRP among patients with coronary 
heart disease.34 The results of a meta-analysis study 
have shown that supplementation with vitamin 
E resulted in decreased levels of CRP.35 However, 
omega-3 administration for six weeks in subjects 
with visceral obesity did not cause any significant 
change in hs-CRP values.36 Co-supplementation 
with omega-3 and vitamin E for six weeks among 
patients with GDM showed no significant changes 
in hs-CRP levels.37 Previous studies reported a 
4.4-fold increase in the relative risk for CVD 
comparing the highest and lowest quartiles of 
CRP, while this increase is only 2.4-fold comparing 
the quartiles of cholesterol.38,39 CRP stimulates 
mononuclear cells to release tissue factors which are 
important in the initiation of coagulation reactions, 
complement activation, and neutralization of 
platelet-activating factor, which in turn promote 
thrombotic response.39 The beneficial effects of 
omega-3 and vitamin E co-supplementation on 
inflammatory cytokines may be due to their effects 
on decreased production of anti-inflammatory 
parameters40 and inhibited activation of nuclear 
factor kappa b.41,42
Our study had some limitations. Due to 
funding limitations, we did not assess the effects 
of omega-3 and vitamin E co-supplementation 
on the measurements of fatty acids profiles and 
vitamin E. In addition, this study was a relatively 
short intervention. Long-term interventions might 
result in better changes in mean levels of CIMT.
C O N C LU S I O N
Co-supplementation with omega-3 and vitamin E 
for 12 weeks in patients with PCOS had beneficial 
effects on CIMT and serum hs-CRP concentration, 
but unchanged NO values.
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